Use of an lgals3bp protein abundance detection reagent in the preparation of a diagnostic reagent for gestational diabetes mellitus

Abstract

The application discloses application of a reagent for detecting LGALS3BP protein abundance in preparation of a tear liquid diagnostic reagent for gestational diabetes mellitus. The application provides a new diagnostic marker for gestational diabetes mellitus diagnosis, and also provides a new diagnostic method for gestational diabetes mellitus diagnosis. Since the diagnosis is performed through tears, the method has the advantages of non-invasiveness, simple operation and rapidness.

Description

Technical Field

[0001] This invention relates to the field of medical molecular testing and diagnostics, specifically to the application of an LGALS3BP protein abundance detection reagent in the preparation of a diagnostic reagent for gestational diabetes mellitus tears. Background Technology

[0002] Gestational diabetes mellitus (GDM) is a condition in which glucose tolerance is first diagnosed during pregnancy in individuals who had normal glucose metabolism before conception. GDM has posed a significant threat to the health of the Chinese population. On the one hand, the prevalence of GDM is increasing due to changing lifestyles and rising childbearing ages. On the other hand, GDM can lead to adverse pregnancy outcomes such as macrosomia (large baby), cesarean section, premature birth, and preeclampsia, and increases the long-term risk of metabolic syndrome in both mother and child. Therefore, effectively controlling GDM is of great importance to the well-being of the Chinese people.

[0003] Currently, the standard clinical diagnostic method for gestational diabetes mellitus is the oral glucose tolerance test (OGTT). The specific method involves ingesting a solution containing 75g of glucose within 5 minutes. Blood samples are collected intravenously before, 1.0, and 2.0 hours after glucose ingestion. Glucose levels in the blood samples are assessed as below 5.1 mmol / L, 10.0 mmol / L, and 8.5 mmol / L, respectively, to determine if the subject's glucose tolerance is normal. The disadvantages of this method are that it is time-consuming and invasive; subjects must wait 2.5 hours to complete the test and have four blood samples collected intravenously, resulting in wasted time and a poor experience for the patient. Therefore, a non-invasive and time-saving diagnostic method for gestational diabetes mellitus urgently needs to be developed.

[0004] Tears are an ideal source of bodily fluids for diagnosing human diseases, possessing advantages such as stable component concentration, ease of collection, and non-invasive collection methods. Therefore, this invention develops a reagent for detecting the abundance of LGALS3BP protein in tears, and its application in the preparation of diagnostic reagents for gestational diabetes mellitus. This invention can be used for non-invasive, convenient, and rapid diagnosis of gestational diabetes mellitus. Summary of the Invention

[0005] In view of this, the purpose of this invention is to provide an application of an LGALS3BP protein abundance detection reagent, which uses tears as the detection target, in a diagnostic reagent for tears in gestational diabetes mellitus.

[0006] To achieve the above objectives, the present invention provides the following technical solution:

[0007] Application of a reagent for detecting the abundance of LGALS3BP protein in the preparation of diagnostic reagents for gestational diabetes mellitus.

[0008] Preferably, the gene encoding the LAGLS3BP protein is LGALS3BP, with a PubMed database ID of 3959 and a full name of galectin 3-binding protein. Its human chromosome location is Chromosome 17,NC_000017.11 (78971255-78979923).

[0009] Preferably, the reagent for detecting the abundance of LGALS3BP protein refers to a reagent capable of detecting the abundance of LGALS3BP protein in a liquid sample.

[0010] Preferably, the LGALS3BP protein abundance detection method includes mass spectrometry or ELISA.

[0011] Preferably, gestational diabetes refers to a condition in which glucose metabolism was normal before pregnancy, but symptoms of glucose intolerance were first diagnosed during pregnancy.

[0012] Preferably, the diagnostic sample for the diagnostic reagent is a tear sample from the subject.

[0013] Preferably, the diagnostic criteria for gestational diabetes mellitus are that the concentration of LGALS3BP in the tear samples of patients with gestational diabetes mellitus is significantly lower than that in the tear samples of normal women.

[0014] Preferably, the standard clinical diagnostic method for the symptoms of glucose intolerance is the oral glucose tolerance test (OGTT).

[0015] The beneficial effects of this invention are as follows: This invention discloses the application of a reagent for detecting the abundance of LGALS3BP protein in the preparation of a diagnostic reagent for gestational diabetes mellitus tears. This invention can be used for non-invasive, convenient, and rapid diagnosis of gestational diabetes mellitus. Attached Figure Description

[0016] To make the objectives, technical solutions, and beneficial effects of this invention clearer, the following figures are provided for illustration:

[0017] Figure 1 For mass spectrometry analysis of LGALS3BP protein levels in the tears of patients with gestational diabetes mellitus;

[0018] Figure 2 An analysis of the accuracy of identifying gestational diabetes mellitus by measuring LGALS3P tear protein levels. Detailed Implementation

[0019] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, so that those skilled in the art can better understand and implement the present invention. However, the embodiments described are not intended to limit the present invention.

[0020] Example 1: Mass spectrometry analysis of LGALS3BP protein levels in the tears of patients with gestational diabetes mellitus

[0021] Tears were collected from women diagnosed with gestational diabetes via oral glucose tolerance test (OGTT) and other women. Total protein was extracted from the tears, and the protein concentration of LGALS3BP in the tear samples was detected by liquid chromatography-mass spectrometry tandem. The results are as follows: Figure 1 As shown. The results showed that the protein concentration of LGALS3BP in tear samples from patients with gestational diabetes mellitus was significantly lower than that in the tear samples of normal women (Student's t-test, This result indicates that tear LGALS3BP protein levels can serve as a biomarker for the diagnosis of gestational diabetes mellitus.

[0022] Example 2: Accuracy analysis of LGALS3P tear protein level in identifying gestational diabetes mellitus

[0023] Tears were collected from women diagnosed with gestational diabetes mellitus by oral glucose tolerance test (OGTT) and normal women. Total protein was extracted from the tears, and the protein concentration of LGALS3BP in the tear samples was detected by ELISA. The ELISA kit was purchased from Abcam (catalog number ab132454). ROC curves were plotted, and the results are shown below. Figure 2 As shown in the figure. The results showed that the AUC value under the ROC curve was 0.8496, indicating that LGAL3BP has a good ability to distinguish gestational diabetes mellitus. Therefore, the level of tear LGALS3BP protein can be used as a biomarker for the diagnosis of gestational diabetes mellitus.

[0024] The above-described embodiments are merely preferred embodiments provided to fully illustrate the present invention, and the scope of protection of the present invention is not limited thereto. Equivalent substitutions or modifications made by those skilled in the art based on the present invention are all within the scope of protection of the present invention. The scope of protection of the present invention is defined by the claims.

Claims

1. Use of a reagent for detecting the abundance of LGALS3BP protein in the manufacture of a diagnostic reagent for gestational diabetes, characterized in that: The coding gene of the LGALS3BP protein is LGALS3BP, Pubmed database ID is 3959, full name is galectin 3 binding protein, human chromosome location is Chromosome 17, NC_000017.11 (78971255-78979923), and the AUC value under the ROC curve of the diagnostic reagent is 0.8496; the diagnostic criteria of gestational diabetes mellitus is that the LGALS3BP concentration in the tear sample of the gestational diabetes mellitus patient is significantly lower than the LGALS3BP concentration in the tear sample of the normal female.

2. Use according to claim 1, characterized in that: The reagent for detecting the abundance of the LGALS3BP protein refers to a reagent capable of detecting the abundance of the LGALS3BP protein in a liquid sample.

3. Use according to claim 1, characterized in that: The LGALS3BP protein abundance detection method comprises mass spectrometry or ELISA.

4. Use according to claim 1, characterized in that: The gestational diabetes mellitus refers to a disease in which the glucose metabolism is normal before pregnancy, and the symptoms of glucose intolerance are first diagnosed during pregnancy.

5. The use according to claim 1, characterized in that: The diagnostic sample of the diagnostic reagent is a tear sample of a subject.

6. Use according to claim 4, characterized in that: The standard clinical diagnostic method of the glucose intolerance symptom is an oral glucose tolerance OGTT test.

Images